Oxaliplatin News and Research

RSS

New treatment combination shows promise for metastatic colorectal cancer patients with rare genetic mutation

An international Phase 3 clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab.

27 Oct 2023

Exploring the link between drugs and microbiota: a growing imperative in precision medicine

The intricate interactions between gut microbiota and drugs.

11 Oct 2023

Subclonal neoantigens present a key roadblock in MMRd tumor immunotherapy success

Researchers evaluated sensitivity to immune checkpoint blockade (ICB) therapy.

20 Sep 2023

Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

Amgen today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on Oct. 5, 2023.

From AMGEN 1 Sep 2023

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.

23 Aug 2023

New anticancer agent activated by ultrasound waves does not have strong side effects

Chemotherapy treatments produce strong side effects. A new agent that accumulates in the tumor tissue and is activated thereby ultrasound waves does not have this problem.

5 Apr 2023

Four-drug chemotherapy regimen provides longer overall survival for metastatic pancreatic ductal adenocarcinoma

A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma.

20 Jan 2023

Study finds novel pathway for understanding why debilitating conditions happen for cancer patients

Severe and persistent disability often undermines the life-saving benefits of cancer treatment. Pain and fatigue -; together with sensory, motor, and cognitive disorders -; are chief among the constellation of side effects that occur with the platinum-based agents used widely in chemotherapy treatments worldwide.

9 Jan 2022

Researchers identify new drug that makes pancreatic cancer cells more vulnerable to chemotherapy

Researchers at Washington University School of Medicine in St. Louis have identified a drug compound that makes pancreatic cancer cells more vulnerable to chemotherapy.

1 Dec 2021

Researchers compare transcriptomic and cytokine responses of colorectal cancer cells

Oncotarget published "Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells" which reported that there was an increase in IL-8 by oxaliplatin and increase in ferritin by cisplatin which may contribute to cancer cell survival.

29 Sep 2021

Discovery may enable the development of new therapies to kill aggressive cancer cells

Vanderbilt faculty and researchers are looking for the "Achilles' heel" of the cancer cells that survive initial chemotherapy.

3 Aug 2021

Study reveals potential risk factors for developing nerve damage after cancer treatment

A low hemoglobin count, older age and high BMI are possible risk factors for developing nerve damage after cancer treatment, a UNSW-led study has found.

4 Mar 2021

Combining PD-1 and VEGF inhibitors with chemotherapy can help control cholangiocarcinoma

Cholangiocarcinoma (CCA) is considered as a diverse group of epithelial cancers characterized by poor outcomes. Cholangiocarcinoma can be divided into three types according to the original position: Intrahepatic Cholangiocarcinoma (ICC), Perihilar Cholangiocarcinoma (PCC), and Distal Extrahepatic Tumors (DET).

3 Feb 2021

New approach can prevent aggressive operation in certain rectal cancer patients

A nonsurgical treatment option for rectal cancer that preserves quality of life is safe for carefully selected patients, according to a new study comparing it with the standard operation.

27 Oct 2020

Study shows how Cisplatin chemotherapy leads to neuronal apoptosis

Despite the great advances in cancer research in recent years, treatments that can cause very severe adverse effects are still used. This is the case of neuropathy caused by chemotherapy with platinum derivatives, such as Cisplatin and Oxaliplatin.

30 Sep 2020

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival.

21 Sep 2020

First clinical trial could become an effective way to deliver chemotherapy to abdominal cancer patients

City of Hope surgical researchers are the first in the nation to open a clinical trial that could one day become an effective way to deliver chemotherapy to abdominal cancer patients who currently have very few treatment options.

11 Aug 2020

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.

19 May 2020

Trial of cancer drug OxaliTex promises lower toxicity and more robust action

Preclinical trials indicate that a drug candidate called OxaliTex can stop the growth of cancer cells completely. OxaliTex appears to be more potent than many other common chemotherapy drugs, with less toxicity and less rapidly counteracted by mechanisms of drug resistance. The study was reported in the journal Proceedings of the National Academy of Sciences in March 2020.

16 Mar 2020

NUS researchers identify new protein to prevent chemotherapy-induced neuropathy

A team of researchers from the NUS Yong Loo Lin School of Medicine has identified a novel protein that would prevent the development of neuropathy in cancer patients who receive chemotherapy.

18 Feb 2020